---
title: "Danaher Stock Has Fallen Far Enough. Buy It Now, Says Analyst"
description: "Danaher Corporation's stock has declined due to weaker-than-expected fourth-quarter earnings and soft demand in the biotech sector. Analysts suggest it may be time to buy, citing Danaher's strong fina"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/231961704.md"
published_at: "2025-03-16T03:30:43.000Z"
---

# Danaher Stock Has Fallen Far Enough. Buy It Now, Says Analyst

> Danaher Corporation's stock has declined due to weaker-than-expected fourth-quarter earnings and soft demand in the biotech sector. Analysts suggest it may be time to buy, citing Danaher's strong financial history, robust cash flow, and a positive outlook for 2025 with expected revenue growth. Despite recent disappointments, the company's commitment to shareholder value through buybacks and dividends makes it an attractive option. However, potential risks include market volatility and sector demand challenges. Investors are advised to weigh these factors before deciding to invest.

Danaher Corporation (DHR) has been on a rollercoaster ride in recent months, with its stock price taking a significant hit due to weaker-than-expected fourth-quarter earnings and soft demand in the biotech and pharmaceutical sectors. However, analysts are now suggesting that the stock has fallen far enough and that it might be time to buy. Let's dive into the details and see if this is a sound investment strategy.

Danaher's recent financial performance has been a mixed bag. The company reported net earnings of $1.1 billion, or $1.49 per diluted common share, for the fourth quarter of 2024, with non-GAAP adjusted diluted net earnings per common share at $2.14. Revenues increased by 2.0% year-over-year to $6.5 billion, and non-GAAP core revenue increased by 1.0%. While these numbers show some growth, they fell short of Wall Street's expectations, leading to a decline in the stock price.

The primary reason for the earnings miss was soft demand for tools and services used in drug development by biotech and pharmaceutical clients. This trend is concerning, as it indicates a potential slowdown in the life sciences and diagnostics sectors, which are Danaher's core businesses. However, it's essential to consider the broader context and the company's long-term prospects.

Danaher has a strong track record of delivering solid financial results and maintaining robust profit margins. In 2022, the company reported a 25.0% year-over-year increase in net earnings for the fourth quarter and a 13.5% year-over-year increase for the full year. This historical performance suggests that danaher has the resilience and strategic focus to navigate through challenging times.

Moreover, Danaher's strong cash flow position allows it to invest in growth opportunities, return capital to shareholders through dividends and share buybacks, and maintain financial flexibility. The company executed a $4.5 billion share buyback in 2024, demonstrating its commitment to returning value to shareholders. Additionally, Danaher increased its quarterly dividend to $0.32 per share, making it an attractive option for income-focused investors.

Looking ahead, Danaher's outlook for the first quarter and full year 2025 indicates that the company expects non-GAAP core revenue to increase by approximately 3% year-over-year. This positive outlook suggests that Danaher is confident in its ability to grow its revenue and maintain its financial health in the future.

However, it's essential to consider the potential risks and challenges that Danaher may face in the near future. Market volatility, soft demand in the biotech and pharmaceutical sectors, and regulatory risks could impact the company's long-term growth prospects and stock performance. Additionally, Danaher's dependency on life sciences and diagnostics, integration of acquisitions, and currency fluctuations pose potential risks.

In conclusion, while Danaher's recent financial performance has been disappointing, the company's strong fundamentals, robust cash flow, and positive outlook for future growth make it an attractive investment option. Analysts' recommendations to buy the stock at its current price level suggest that the market has overreacted to the recent earnings miss, and the stock has fallen far enough to present a buying opportunity. However, investors should carefully consider the potential risks and challenges before making an investment decision.

### Related Stocks

- [DHR.US - Danaher](https://longbridge.com/en/quote/DHR.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 在丹纳赫的重大新闻发布后，现在追逐麦斯莫医疗的股票是否为时已晚？ | 追逐麦斯莫医疗股票是否为时已晚，因丹纳赫重大消息？ | [Link](https://longbridge.com/en/news/276240846.md) |
| 丹纳赫（DHR）在近期股价走弱后是否具有吸引力？ | 丹纳赫（DHR）股票最近在过去一周下跌了 6.1%，在过去一个月下跌了 12.6%，目前价格约为 206 美元。折现现金流（DCF）分析表明，该股票被低估了 10%，每股内在价值为 229.39 美元。然而，其市盈率为 40.52 倍，超过 | [Link](https://longbridge.com/en/news/276201502.md) |
| Madrigal 制药｜8-K：2025 财年 Q4 营收 3.21 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276330350.md) |
| 美股盘中速递：NovaBay 制药涨 26.73%，剥离非核心业务引发市场热情与信心提升 | NovaBay 制药涨 26.73%；强生跌 2.40%，成交额达到 7.66 亿美元；礼来跌 1.65%，成交额达到 7.35 亿美元；默克涨 0.01%，成交额达到 2.06 亿美元；阿斯利康跌 0.15%，市值达到 3197 亿美元。 | [Link](https://longbridge.com/en/news/276459970.md) |
| Ultragenyx 制药｜8-K：2025 财年营收 6.73 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/275809108.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.